Dr. Snyder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 E Duarte Rd
Duarte, CA 91010Phone+1 626-359-8111- Is this information wrong?
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1978 - 1980
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1977 - 1978
Harvard Medical SchoolClass of 1977
Certifications & Licensure
CA State Medical License 1984 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses Start of enrollment: 2015 Jun 30
Publications & Presentations
PubMed
- 7 citationsOutcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL.Ibrahim Aldoss, Dongyun Yang, Vanina Tomasian, Sally Mokhtari, Ryan Jackson, Zhaohui Gu, Milhan Telatar, Hooi Yew, Monzr M Al Malki, Amandeep Salhotra, Samer Khaled, H...> ;Blood Advances. 2022 Sep 13
- 4 citationsLong-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.Colton Ladbury, George Somlo, Andy Dagis, Dongyun Yang, Saro Armenian, Joo Y Song, Firoozeh Sahebi, Ricardo Spielberger, Leslie Popplewell, Pablo Parker, Stephen Forma...> ;Transplantation and Cellular Therapy. 2022 Jul 1
- 9 citationsPeritransplant Ruxolitinib Administration is Safe and Effective in Patients with Myelofibrosis: a Pilot Open-Label Study.Haris Ali, Ni-Chun Tsai, Timothy W. Synold, Sally Mokhtari, Weimin Tsai, Joycelynne Palmer, Tracey Stiller, Amandeep Salhotra, Syed Rahmanuddin, Vinod Pullarkat, Ji-Li...> ;Blood Advances. 2021 Sep 28
- Join now to see all
Abstracts/Posters
- Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
2 City of Hope Physicians Recognized for Compassionate Patient Care, Innovative LeadershipDecember 8th, 2020
Imetelstat Promising Across Myeloproliferative NeoplasmsSeptember 4th, 2015
Hospital Affiliations
City of Hope Comprehensive Cancer CenterDuarte, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
